{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T06:05:03Z","timestamp":1779602703050,"version":"3.53.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,23]]},"DOI":"10.7759\/cureus.109528","type":"journal-article","created":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T05:50:29Z","timestamp":1779601829000},"source":"Crossref","is-referenced-by-count":0,"title":["Oral Small-Molecule Therapies Versus Biologic Agents in Moderate-to-Severe Ulcerative Colitis: A Systematic Review of Pivotal Phase 3 Trials"],"prefix":"10.7759","author":[{"given":"Okasha","family":"Zulfiqar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talha","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam","family":"Mohayy Ud Din","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaheer Ud Din","family":"Babar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabir","family":"Zarif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-1758047","article-title":"Diagnosis and monitoring of ulcerative colitis","volume":"35","author":"Murphy ME","year":"2022","unstructured":"Murphy ME, Bhattacharya S, Axelrad JE. Diagnosis and monitoring of ulcerative colitis. Clin Colon Rectal Surg. 2022, 35:421-7. 10.1055\/s-0042-1758047","journal-title":"Clin Colon Rectal Surg"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2147\/IJGM.S532534","article-title":"Mechanism of morbidity based on ulcerative colitis: a review of traditional Chinese medicine treatment of ulcerative colitis","volume":"18","author":"Huang Y","year":"2025","unstructured":"Huang Y, Ma Z, Xu X, Liu Z. Mechanism of morbidity based on ulcerative colitis: a review of traditional Chinese medicine treatment of ulcerative colitis. Int J Gen Med. 2025, 18:5811-29. 10.2147\/IJGM.S532534","journal-title":"Int J Gen Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.01.018","article-title":"Ulcerative colitis","volume":"94","author":"Feuerstein JD","year":"2019","unstructured":"Feuerstein JD, Moss AC, Farraye FA. Ulcerative colitis. Mayo Clin Proc. 2019, 94:1357-73. 10.1016\/j.mayocp.2019.01.018","journal-title":"Mayo Clin Proc"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-024-00207-w","article-title":"Ulcerative colitis: molecular insights and intervention therapy","volume":"5","author":"Liang Y","year":"2024","unstructured":"Liang Y, Li Y, Lee C, Yu Z, Chen C, Liang C. Ulcerative colitis: molecular insights and intervention therapy. Mol Biomed. 2024, 5:42. 10.1186\/s43556-024-00207-w","journal-title":"Mol Biomed"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13237026","article-title":"Optimal management of patients with moderate-to-severe inflammatory bowel disease","volume":"13","author":"Purnak T","year":"2024","unstructured":"Purnak T, Ertan A. Optimal management of patients with moderate-to-severe inflammatory bowel disease. J Clin Med. 2024, 13:7026. 10.3390\/jcm13237026","journal-title":"J Clin Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy004","article-title":"Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with inflammatory bowel diseases: a systematic review and meta-analysis","volume":"12","author":"Singh S","year":"2018","unstructured":"Singh S, George J, Boland BS, Vande Casteele N, Sandborn WJ. Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with inflammatory bowel diseases: a systematic review and meta-analysis. J Crohns Colitis. 2018, 12:635-43. 10.1093\/ecco-jcc\/jjy004","journal-title":"J Crohns Colitis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4292\/wjgpt.v16.i4.110472","article-title":"Emerging role of Janus kinase inhibitors in ulcerative colitis management","volume":"16","author":"Ahsan MU","year":"2025","unstructured":"Ahsan MU, Sajid SL, Balach R, Daniyal M, Ain NU, Mudasir M. Emerging role of Janus kinase inhibitors in ulcerative colitis management. World J Gastrointest Pharmacol Ther. 2025, 16:110472. 10.4292\/wjgpt.v16.i4.110472","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-024-08792-0","article-title":"Small molecules, big results: how JAK inhibitors have transformed the treatment of patients with IBD","volume":"70","author":"Fansiwala K","year":"2025","unstructured":"Fansiwala K, Sauk JS. Small molecules, big results: how JAK inhibitors have transformed the treatment of patients with IBD. Dig Dis Sci. 2025, 70:469-77. 10.1007\/s10620-024-08792-0","journal-title":"Dig Dis Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13112655","article-title":"Sphingosine-1-phosphate (S1P) receptor modulators for the treatment of inflammatory bowel disease (IBD): mechanisms, clinical evidence, and practical insights","volume":"13","author":"Shields N","year":"2025","unstructured":"Shields N, Colwill M, Raspa V, Twum-Danso Y, Poullis A, Patel K, Honap S. Sphingosine-1-phosphate (S1P) receptor modulators for the treatment of inflammatory bowel disease (IBD): mechanisms, clinical evidence, and practical insights. Biomedicines. 2025, 13:2655. 10.3390\/biomedicines13112655","journal-title":"Biomedicines"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14165789","article-title":"Efficacy of biologic agents and small molecules for endoscopic improvement and mucosal healing in patients with moderate-to-severe ulcerative colitis: systematic review and meta-analysis","volume":"14","author":"Mademlis C","year":"2025","unstructured":"Mademlis C, Katsoula A, Koufakis T, et al.. Efficacy of biologic agents and small molecules for endoscopic improvement and mucosal healing in patients with moderate-to-severe ulcerative colitis: systematic review and meta-analysis. J Clin Med. 2025, 14:5789. 10.3390\/jcm14165789","journal-title":"J Clin Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/1524839919893361","article-title":"A review of the PubMed PICO tool: using evidence-based practice in health education","volume":"21","author":"Brown D","year":"2020","unstructured":"Brown D. A review of the PubMed PICO tool: using evidence-based practice in health education. Health Promot Pract. 2020, 21:496-8. 10.1177\/1524839919893361","journal-title":"Health Promot Pract"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis","volume":"317","author":"Schroeder KW","year":"1987","unstructured":"Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med. 1987, 317:1625-9. 10.1056\/NEJM198712243172603","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn WJ","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, et al.. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017, 376:1723-36. 10.1056\/NEJMoa1606910","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese S","year":"2022","unstructured":"Danese S, Vermeire S, Zhou W, et al.. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022, 399:2113-28. 10.1016\/S0140-6736(22)00581-5","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn WJ","year":"2021","unstructured":"Sandborn WJ, Feagan BG, D'Haens G, et al.. Ozanimod as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2021, 385:1280-91. 10.1056\/NEJMoa2033617","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn WJ","year":"2023","unstructured":"Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al.. Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies. Lancet. 2023, 401:1159-71. 10.1016\/S0140-6736(23)00061-2","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts P","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, et al.. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005, 353:2462-76. 10.1056\/NEJMoa050516","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn WJ","year":"2012","unstructured":"Sandborn WJ, van Assche G, Reinisch W, et al.. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012, 142:257-65.e1-3. 10.1053\/j.gastro.2011.10.032","journal-title":"Gastroenterology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan BG","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, et al.. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013, 369:699-710. 10.1056\/NEJMoa1215734","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands BE","year":"2019","unstructured":"Sands BE, Sandborn WJ, Panaccione R, et al.. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019, 381:1201-14. 10.1056\/NEJMoa1900750","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0273-0","article-title":"JAK-STAT pathway targeting for the treatment of inflammatory bowel disease","volume":"17","author":"Salas A","year":"2020","unstructured":"Salas A, Hernandez-Rocha C, Duijvestein M, et al.. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020, 17:323-37. 10.1038\/s41575-020-0273-0","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3390\/ph18050740","article-title":"State-of-the-art evidence for clinical outcomes and therapeutic implications of Janus kinase inhibitors in moderate-to-severe ulcerative colitis: a narrative review","volume":"18","author":"Choi Y","year":"2025","unstructured":"Choi Y, Lee S, Kim HJ, Park T, Kwack WG, Yang S, Chung EK. State-of-the-art evidence for clinical outcomes and therapeutic implications of Janus kinase inhibitors in moderate-to-severe ulcerative colitis: a narrative review. Pharmaceuticals (Basel). 2025, 18:740. 10.3390\/ph18050740","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.55730\/1300-0144.5722","article-title":"Oral small molecule agents in management of ulcerative colitis: fact or fancy","volume":"53","author":"Kasapo\u011flu B","year":"2023","unstructured":"Kasapo\u011flu B, Ertan A. Oral small molecule agents in management of ulcerative colitis: fact or fancy. Turk J Med Sci. 2023, 53:1526-36. 10.55730\/1300-0144.5722","journal-title":"Turk J Med Sci"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3390\/ph18030308","article-title":"Small molecules in the treatment of acute severe ulcerative colitis: a review of current evidence","volume":"18","author":"Pellegrino R","year":"2025","unstructured":"Pellegrino R, Imperio G, De Costanzo I, et al.. Small molecules in the treatment of acute severe ulcerative colitis: a review of current evidence. Pharmaceuticals (Basel). 2025, 18:308. 10.3390\/ph18030308","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/492293-oral-small-molecule-therapies-versus-biologic-agents-in-moderate-to-severe-ulcerative-colitis-a-systematic-review-of-pivotal-phase-3-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T05:50:30Z","timestamp":1779601830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/492293-oral-small-molecule-therapies-versus-biologic-agents-in-moderate-to-severe-ulcerative-colitis-a-systematic-review-of-pivotal-phase-3-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.109528","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,23]]}}}